Individualized treatment strategy for esophageal cancer based on the expression of microRNAs in preoperative biopsy specimens.

2015 Fiscal Year Final Research Report

• Project/Area Number: 24591950
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Japanese Foundation for Cancer Research (2013-2015); Kumamoto University (2012)
• Principal Investigator: Msayuki Watanabe 公益財団法人がん研究会, その他部局等, その他 (80254639)
• Co-Investigator(Kenkyū-buntansha): ISHIMOTO Takatsugu 熊本大学, 大学院生命科学研究部, 特任助教 (00594889) ; BABA Yoshifumi 熊本大学, 医学部附属病院, 助教 (20599708)
• Research Collaborator: KURASHIGE Junji ; TANAKA Yohei ; SHIGAKI Hironobu ; ETO Kojiro ; HARADA Kazuto
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: 食道癌 / 化学療法感受性 / 個別化治療 / mircoRNA / FBXW7 / Ribophorin II / microRNA-223 / microRNA-21

Outline of Final Research Achievements

The aim of this study was to evaluate the possibility of individualized treatment strategy for esophageal cancer based on the expression of microRNAs in pretreatment biopsy specimens. We revealed that miR-223, which influenced sensitivity to chemotherapeutic agents through regulating the expression of FBXW7, was overexpressed in esophageal cancer tissues compared to normal esophageal epithelium. We also demonstrated that the expression levels of Ribophorin II (RPN2) can be a predictor of sensitivity to Docetaxel. In addition, we found the levels of serum miR-21 or exosomal miR-21 were higher in esophageal cancer patients than in controls and they can be biomarkers for chemosensitivity.

Free Research Field

消化器外科学